Apogee Therapeutics, Inc. (APGE)

Market Cap	2.26B
Revenue (ttm)	n/a
Net Income (ttm)	-205.39M
Shares Out	57.20M
EPS (ttm)	-3.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	703,918
Open	39.49
Previous Close	37.29
Day's Range	38.69 - 40.71
52-Week Range	26.20 - 63.50
Beta	n/a
Analysts	Strong Buy
Price Target	91.33 (+131.33%)
Earnings Date	May 12, 2025

About APGE

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: APGE
• Website: https://www.apogeetherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price forecast is $91.33, which is an increase of 131.33% from the latest price.

Price Target

$91.33

(131.33% upside)

Analyst Consensus: Strong Buy